Study guide
5.6 Disease-Site MNT: Hematologic Malignancies & HSCT
CDR CSO Board Certified Specialist in Oncology Nutrition Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the CDR CSO Exam & Certification Logistics 1.2 How to Navigate and Master This Study Guide
2 Chapter 2: Cancer & Cancer Treatment Modalities
2.1 Cancer Biology, Pathophysiology, & Carcinogenesis 2.2 Staging, Grading, & Surgical Oncology Interventions 2.3 Radiation Therapy Modalities & Radiation Toxicities 2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging 2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy 2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)
3 Chapter 3: Comprehensive Nutrition Assessment & Malnutrition Staging
3.1 Patient-Generated Subjective Global Assessment (PG-SGA) 3.2 GLIM Criteria for Malnutrition Diagnosis in Oncology 3.3 Cancer Cachexia Staging & Pathophysiology (Fearon Consensus) 3.4 Estimating Energy & Protein Requirements (ESPEN Guidelines) 3.5 Anthropometrics & Body Composition Analysis (DEXA, BIA, CT) 3.6 Biochemical & Inflammatory Marker Interpretation 3.7 Nutrition-Focused Physical Exam (NFPE) in Oncology 3.8 Medical, Oncologic, and Treatment History Review 3.9 Diet and Lifestyle History: Methods and Interpretation 3.10 Cultural, Psychosocial, and Socioeconomic Factors
4 Chapter 4: Nutrition-Impact Side Effect Management & Pharmacotherapy
4.1 Upper GI Symptoms: Anorexia, Early Satiety, Nausea, & Vomiting 4.2 Oral & Mucosal Toxicities: Stomatitis, Mucositis, Dysgeusia, & Xerostomia 4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation 4.4 Pancreatic Exocrine Insufficiency & PERT Dosing Protocols 4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics 4.6 Oncologic Emergencies: Tumor Lysis, Hypercalcemia, & Superior Vena Cava Syndrome
5 Chapter 5: Specialized Nutrition Interventions, Disease-Site MNT & Care Coordination
5.1 Enteral Nutrition: Access, Indications, & Formula Selection 5.2 Prophylactic Enteral Tubes in Head & Neck Cancer 5.3 Parenteral Nutrition in Oncology: Indications & Management 5.4 Disease-Site MNT: Head & Neck, Esophageal, & Gastric Cancers 5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers 5.6 Disease-Site MNT: Hematologic Malignancies & HSCT 5.7 Refeeding Syndrome & Cyclic Nutrition Support Protocols 5.8 Referrals, Care Coordination, and Transitions of Care 5.9 Monitoring, Evaluation, and Nutrition Outcomes
6 Chapter 6: Patient Education, Counseling, & Herbal/Supplement Safety
6.1 Patient Counseling & Motivational Interviewing 6.2 Managing Sensory Alterations & Taste Changes 6.3 Complementary & Alternative Medicine (CAM) in Oncology 6.4 Dietary Supplement & Herbal Safety during Cancer Therapy 6.5 Key Drug-Nutrient Interactions in Oncology
7 Chapter 7: Cancer Survivorship, Palliative Nutrition, & End-of-Life Ethics
7.1 Food Safety & Neutropenic Dietary Evidence 7.2 Cancer Survivorship: AICR/WCRF Guidelines & Lifestyle 7.3 Weight Management & Metabolic Health in Survivorship 7.4 Palliative Nutrition & Goals of Care Alignment 7.5 End-of-Life Ethical Considerations & Bioethics
5.6 Disease-Site MNT: Hematologic Malignancies & HSCT
Key Takeaways Explain This Topic AI
Advanced lung cancer increases resting energy expenditure by 15-25% due to the increased work of breathing (WOB); MNT mandates energy-dense, low-volume, small frequent feedings.
High-dose dexamethasone therapy for brain tumors causes steroid-induced hyperglycemia, rapid weight gain, hyperphagia, and muscle wasting, requiring aggressive carbohydrate control and protein preservation.
Hematologic malignancy patients undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) require strict safe food handling practices and structured nutrition support for severe conditioning mucositis.
Acute gastrointestinal Graft-versus-Host Disease (GI GVHD) management requires a 4-Phase step-up dietary protocol: Phase I Bowel Rest (NPO + TPN), Phase II Isotonic Clear Liquids, Phase III Low-Fat (<10g/day) Low-Lactose Low-Fiber Soft Foods, and Phase IV Transition to Regular Diet.
Last updated: August 2026
5.6 Disease-Site MNT: Hematologic Malignancies & HSCT
Quick Summary: Nutritional care across thoracic, central nervous system, and hematologic malignancies requires managing systemic inflammatory metabolic demands, drug toxicities, and immunologic transplant complications. Lung cancer increases Resting Energy Expenditure (REE) by 15–25% via increased Work of Breathing (WOB). Corticosteroid therapy for brain tumors induces severe hyperglycemia and muscle catabolism. Allogeneic HSCT recipients who develop acute GI Graft-versus-Host Disease (GI GVHD) must follow a mandatory 4-Phase step-up diet starting with complete bowel rest (NPO + TPN).
1. Lung Cancer MNT & Work of Breathing
Patients with Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) exhibit high rates of cancer cachexia driven by systemic inflammatory elevation (high C-reactive protein, IL-6, TNF-alpha).
Clinical Nutrition Challenges
Work of Breathing (WOB) : Severe dyspnea and chronic obstructive pulmonary disease (COPD) co-morbidities increase diaphragm workload, raising Resting Energy Expenditure (REE) by 15% to 25% above predicted baseline.
Early Satiety & Dyspnea while Eating : Chewing and swallowing interrupt breathing, worsening hypoxia.
MNT Interventions : Prescribe energy-dense, small-volume meals (1.5–2.0 kcal/mL liquids, concentrated puddings) ; advise resting 30 minutes prior to meals; schedule bronchodilators before meals; provide continuous supplemental oxygen during dining.
2. Brain Tumors MNT (Glioblastoma / Astrocytoma)
Brain tumor management centers on controlling adverse effects from high-dose corticosteroid therapy (Dexamethasone) and managing cranial nerve deficits.
Corticosteroid (Dexamethasone) Toxicities & MNT
Steroid-Induced Hyperglycemia : Corticosteroids induce peripheral insulin resistance and hepatic gluconeogenesis. Enforce strict carbohydrate-controlled diet (consistent carbohydrate distribution across meals, limiting refined sugars).
Steroid Hyperphagia & Rapid Weight Gain : Dexamethasone stimulates appetite center pathways, driving excessive intake. Emphasize high-volume, low-calorie, high-fiber vegetables and lean proteins to prevent rapid fat mass gain.
Steroid Myopathy & Protein Catabolism : High doses accelerate skeletal muscle breakdown. Provide 1.2–1.5 g protein/kg/day .
Cranial Nerve Dysphagia : Brainstem lesions or cranial nerve IX, X, XII palsies cause severe aspiration risk requiring SLP evaluation and IDDSI texture modifications.
3. Hematologic Malignancies & HSCT Diet Protocols
Patients undergoing myeloablative conditioning chemotherapy and Hematopoietic Stem Cell Transplantation (HSCT) experience prolonged neutropenia (ANC <500/mcL), total mucosal breakdown (conditioning mucositis), and risk of Graft-versus-Host Disease (GVHD) .
Food Safety Guidelines for Immunosuppressed / Neutropenic Patients
Traditional highly restrictive "neutropenic diets" are increasingly replaced by modern Safe Food Handling Practices (FDA/CDC Guidelines):
Avoid raw or undercooked meat, poultry, seafood, and eggs.
Avoid unpasteurized milk, cheese, and juices.
Wash all fresh fruits and vegetables thoroughly under running tap water; peel thick-skinned fruits.
Avoid raw honey, unpasteurized beer, and deli meats unless heated to steaming ( 165 ∘ F 165^\circ F 16 5 ∘ F ).
Acute GI Graft-versus-Host Disease (GI GVHD) 4-Phase Step-Up Diet
Allogeneic HSCT recipients can develop acute GI GVHD (donor T-cell attack on recipient intestinal mucosa), presenting with voluminous green watery diarrhea (>1.5–2.0 L/day), severe abdominal cramping, mucosal sloughing, and GI bleeding.
GVHD Diet Phase Clinical Criteria & Objective Permitted Dietary Items Strict Exclusions
Phase I: Bowel Rest Complete NPO. Goal: Bowel rest, decrease intestinal motility, manage fluid/electrolyte balance via TPN. Total Parenteral Nutrition (TPN) only. All oral intake (NPO) .
Phase II: Isotonic Liquids Stool volume decreases (<500 mL/day). Test gut absorptive capacity with isotonic liquids ( < 300 mOsm/kg <300 \text{ mOsm/kg} < 300 mOsm/kg ). Isotonic electrolyte drinks, clear broth, diluted juices, oral rehydration solutions. Hypertonic beverages, milk/lactose, carbonated drinks, caffeine.
Phase III: Re-introduction Soft Sustained low stool volume. Introduce soft, low-residue, low-fat, low-lactose items. Rice, bananas, applesauce, plain white toast, boiled chicken breast, egg whites. Fat >10 g/day , lactose, raw fruits/vegetables, high-fiber, acidic/spicy foods.
Phase IV: Transition Regular Normalizing stool output. Gradual addition of single foods every 24–48 hours. Progressively add healthy fats, cooked vegetables, dairy (if tolerated). Foods triggering immediate diarrhea or cramps.
- Worked Case Example: Acute GI GVHD Management
- Patient Scenario
A 35-year-old male Day +45 post-allogeneic HSCT develops 2,100 mL/day of green watery diarrhea, severe abdominal cramping, and mucosal sloughing.
Diagnostic & MNT Management
Diagnosis : Grade 3 Acute GI GVHD.
Phase I Management : Place patient on complete NPO (bowel rest) and initiate Total Parenteral Nutrition (TPN) providing 1.5 g protein/kg/day and GIR 3.5 mg/kg/min.
Phase II Advancement : On Day +52, stool output decreases to 350 mL/day. Initiate Phase II isotonic clear liquids (oral rehydration solution, clear broth) while tapering TPN.
Phase III Advancement : On Day +55, symptom control is maintained. Progress to Phase III low-fat (<10 g/day), lactose-free, low-residue soft foods (boiled rice, egg whites, applesauce).